Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154957 | 0.98 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAPOLBHPGDALDH1A1 | |
| SCHEMBL4157341 | 0.86 | MAPT (0.47) | SMN1; SMN2LMNAHPGDNPC1RAB9A | |
| SCHEMBL4156660 | 0.86 | MEN1 (0.50) | SMN1; SMN2LMNAPOLBHPGDTP53 | |
| SCHEMBL10399266 | 0.80 | HPGD (0.51) | SMN1; SMN2POLBHPGDALDH1A1NPC1 | |
| SCHEMBL10388494 | 0.79 | HPGD (0.51) | SMN1; SMN2LMNAPOLBHPGDALDH1A1 | |
| SCHEMBL10388311 | 0.79 | NPC1 (0.47) | HPGDALDH1A1NPC1RAB9ATP53 | |
| SCHEMBL10399327 | 0.75 | HPGD (0.42) | HPGDALDH1A1NPC1HTTTSHR | |
| SCHEMBL969710 | 0.74 | HPGD (0.52) | LMNAHPGDALDH1A1NPC1HTT | |
| SCHEMBL424048 | 0.73 | HPGD (0.52) | SMN1; SMN2LMNAPOLBHPGDALDH1A1 | |
| SCHEMBL28241327 | 0.73 | SCN9A (0.37) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | SMN1; SMN2 4602/4885LMNA 4492/4885POLB 3867/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | SMN1; SMN2 4602/4885LMNA 4492/4885POLB 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.